AEZS.TO
Aeterna Zentaris Inc
Price:
4.12
CAD
Volume:
619
United States | Biotechnology
No data available for this ticker
AEZS.TO Probability of Bankruptcy
The Probability of Bankruptcy of Aeterna Zentaris Inc (AEZS.TO) is 0% . This number represents the probability that AEZS.TO will face financial distress in the next 24 months given its current fundamentals and market conditions.
Multiple factors are taken into account when calculating AEZS.TO's probability of bankruptcy : Altman Z-score, Beneish M-score, financial position, macro environments, academic research about distress risk and more.
AEZS.TO - Historical Solvency Measures
to of
Page of
AEZS.TO - ESG ratings
ESG ratings are directly linked to the cost of capital and AEZS.TO's ability to raise funding, both of which can significantly affect the probability of Aeterna Zentaris Inc going bankrupt.
ESG Score
0
Environment Score
0
Social Score
0
Governance Score
0
| Returns | |
| Historical Returns (5 day) | -2.6% |
| Historical Returns (MTD) | -16.6% |
| Historical Returns (YTD) | -31.22% |
| Historical Returns (13 week) | -52.64% |
| Historical Returns (26 week) | -61.82% |
| Historical Returns (52 week) | -38.43% |
| Efficiency | |
| Asset Turnover | 0.06 |
| Receiveable Turnover | 6.01 |
| Gross Margin | 91.1% |
| Operating Margin | - |
| Pretax Margin | - |
| Net Margin | - |
| Return on Asset (ROA) | -45.77 |
| Return on Equity (ROE) | -83.44 |
| Return on Investments (ROI) | -82.57 |
| Price Metrics | |
| Market Cap (M) | 15.5 |
| Enterprise Value (M) | -24.4 |
| 52 Week High | 10.24 |
| 52 Week Low | 3.78 |
| Beta | 1.75 |
| Average Volume (10 day) | 0 |
| Average Volume (3 month) | 0 |
| Price / Earnings (P/E) | - |
| Price / Sales (P/S) | 8.2 |
| Earnings | |
| EPS | -10.75 |
| Revenue CAGR (5 year) | -30.07% |
| Risk | |
| Current Ratio | 5.94 |
| Quick Ratio | 5.68 |
AEZS.TO - Peer Comparisons
| Ticker | Company Name | Beta | Probability of Bankruptcy |
| a | |||
| ATOS | Atossa Therapeutics Inc | 2.36 | 8.3% |
| CELC | Celcuity Inc | 1.36 | 47% |
| FENC | Fennec Pharmaceuticals Inc | 2.07 | 23.7% |
| XFOR | X4 Pharmaceuticals Inc | 0.76 | 80% |